Literature DB >> 17056199

Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy.

Tae Hyun Kim1, Dae Yong Kim, Joong-Won Park, Seong Hoon Kim, Joon-Il Choi, Hyun Beom Kim, Woo Jin Lee, Sang Jae Park, Eun Kyung Hong, Chang-Min Kim.   

Abstract

PURPOSE: To identify the dose-volumetric parameters associated with the risk of radiation-induced hepatic toxicity (RIHT) in hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. METHODS AND MATERIALS: A total of 105 hepatocellular carcinoma patients underwent three-dimensional conformal radiotherapy (total dose range, 44-58.5 Gy; median, 54). RIHT was scored within 4 months of completing three-dimensional conformal radiotherapy. The dose-volume parameters analyzed were the gross tumor volume; normal liver volume; total liver volume; radiation dose; mean dose to the normal liver; percentage of the normal liver volume receiving > or =20, > or =25, > or =30, > or =35, and > or =40 Gy; percentage of the total liver volume receiving > or =20, > or =25, > or =30, > or =35, and > or =40 Gy; and the normal tissue complication probability.
RESULTS: Of the 105 patients, Grade 1 RIHT was observed in 21 (20.0%), Grade 2 in 7 (6.7%), Grade 3 in 5 (4.8%), and Grade 4 in 1 (1.0%) patient. No fatal Grade 5 RIHT developed. On multivariate analysis for predicting Grade 2 or worse RIHT, the total liver volume receiving > or =30 Gy was the only significant parameter (p < 0.001). Grade 2 or worse RIHT was observed in only 2 (2.4%) of 85 patients with a total liver volume receiving 30 Gy of < or =60% and in 11 (55.0%) of 20 patients with >60% (p < 0.001).
CONCLUSION: The total liver volume receiving > or =30 Gy appears to be a useful dose-volumetric parameter for predicting the risk of RIHT. This volume should be limited to < or =60% whenever possible to minimize the risk of Grade 2 or worse RIHT.

Entities:  

Mesh:

Year:  2006        PMID: 17056199     DOI: 10.1016/j.ijrobp.2006.08.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  55 in total

1.  The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus.

Authors:  Shohei Komatsu; Takumi Fukumoto; Yusuke Demizu; Daisuke Miyawaki; Kazuki Terashima; Yasue Niwa; Masayuki Mima; Osamu Fujii; Ryohei Sasaki; Isamu Yamada; Yuichi Hori; Yoshio Hishikawa; Mitsuyuki Abe; Yonson Ku; Masao Murakami
Journal:  J Gastroenterol       Date:  2011-04-23       Impact factor: 7.527

2.  RapidArc vs intensity-modulated radiation therapy for hepatocellular carcinoma: a comparative planning study.

Authors:  J M Park; K Kim; E K Chie; C H Choi; S J Ye; S W Ha
Journal:  Br J Radiol       Date:  2012-07       Impact factor: 3.039

Review 3.  Radiation-associated liver injury.

Authors:  Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

4.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

5.  Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials.

Authors:  Hee Chul Park; Jeong Il Yu; Jason Chia-Hsien Cheng; Zhao Chong Zeng; Ji Hong Hong; Michael Lian Chek Wang; Mi Sook Kim; Kwan Hwa Chi; Po-Ching Liang; Rheun-Chuan Lee; Wan-Yee Lau; Kwang Hyub Han; Pierce Kah-Hoe Chow; Jinsil Seong
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

6.  Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Sung Uk Lee; Joong-Won Park; Tae Hyun Kim; Yeon-Joo Kim; Sang Myung Woo; Young-Hwan Koh; Woo Jin Lee; Sang-Jae Park; Dae Yong Kim; Chang-Min Kim
Journal:  Strahlenther Onkol       Date:  2014-03-04       Impact factor: 3.621

7.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 8.  Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma.

Authors:  Chihwan Choi; Gi Hong Choi; Tae Hyun Kim; Masatoshi Tanaka; Mao-Bin Meng; Jinsil Seong
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

9.  Helical tomotherapy for single and multiple liver tumours.

Authors:  Tsair-Fwu Lee; Pei-Ju Chao; Fu-Min Fang; Te-Jen Su; Stephen W Leung; Hsuan-Chih Hsu
Journal:  Radiat Oncol       Date:  2010-06-24       Impact factor: 3.481

10.  Comparison of coplanar and noncoplanar intensity-modulated radiation therapy and helical tomotherapy for hepatocellular carcinoma.

Authors:  Chen-Hsi Hsieh; Chia-Yuan Liu; Pei-Wei Shueng; Ngot-Swan Chong; Chih-Jen Chen; Ming-Jen Chen; Ching-Chung Lin; Tsang-En Wang; Shee-Chan Lin; Hung-Chi Tai; Hui-Ju Tien; Kuo-Hsin Chen; Li-Ying Wang; Yen-Ping Hsieh; David Y C Huang; Yu-Jen Chen
Journal:  Radiat Oncol       Date:  2010-05-23       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.